Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

20.06 -0.78 (-3.74%)
Streaming Delayed Price Updated: 12:48 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More ↗
Via The Motley Fool
News headline image
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate ↗
FDA extends review of Denali Therapeutics' tividenofusp alfa for Hunter syndrome to April 2026; analysts remain confident in its approval prospects. 
Via Benzinga
News headline image
What Happened To Denali Therapeutics Stock Wednesday? ↗
Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the... 
Via Benzinga
News headline image
4 Analysts Assess Denali Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Denali Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Denali Therapeutics ↗
 
Via Benzinga
News headline image
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback ↗
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug. 
Via Benzinga
News headline image
Why Is Denali Therapeutics Stock Trading Higher On Wednesday? ↗
Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization. 
Via Benzinga
News headline image
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected ↗
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025. 
Via Benzinga
News headline image
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗
One analyst says the six-month study was too short and the benefits could appear over time. 
Via Investor's Business Daily
News headline image
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
News headline image
Where Denali Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday ↗
 
Via Benzinga
News headline image
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why ↗
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. 
Via Benzinga
News headline image
A Biotech Breakout Will Be Led By Small Caps ↗
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
News headline image
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024 ↗
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Denali Therapeutics Stock Gets Technical Rating Upgrade ↗
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs ↗
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. 
Via InvestorPlace
News headline image
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 ↗
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
To the Moon and Beyond: 7 Stocks With Cosmic Potential ↗
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. 
Via InvestorPlace
News headline image
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
News headline image
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst ↗
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
News headline image
3 Biotech Stocks to Buy for the Next Bull Run: February 2024 ↗
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
News headline image
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth ↗
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today. 
Via InvestorPlace
News headline image
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.